Next Article in Journal
In Silico ADME Profiling of Salubrinal and Its Analogues
Next Article in Special Issue
Therapeutic Potential of Mitotic Kinases’ Inhibitors in Cancers of the Gastrointestinal System
Previous Article in Journal / Special Issue
Pharmacogenetic Perspective for Optimal Gout Management
 
 
Case Report

Primary Obsessive Slowness: A Complex Presentation and Treatment Difficulties

1
Sree Chitra Tirunal Institute for Medical Sciences & Technology, Thiruvananthapuram 695011, India
2
Psychiatry Unit, Department of Health Sciences, University Magna Graecia of Catanzaro, Viale Europa, 88100 Catanzaro, Italy
3
Department of Studies on Language and Culture, University of Modena and Reggio Emilia, 41121 Modena, Italy
4
Department of Humanities, Social Sciences and Cultural Industries, University of Parma, 43121 Parma, Italy
5
Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru 560029, India
6
North Western Mental Health, Melbourne, VIC 230004, Australia
*
Author to whom correspondence should be addressed.
Academic Editor: Fabrizio Schifano
Future Pharmacol. 2022, 2(2), 153-159; https://doi.org/10.3390/futurepharmacol2020012
Received: 16 April 2022 / Revised: 7 May 2022 / Accepted: 10 May 2022 / Published: 13 May 2022
(This article belongs to the Special Issue Feature Papers in Future Pharmacology)
Obsessive slowness is described as a complex and disabling clinical syndrome that causes extreme slowness in performing tasks, with potential personal and functional impairment. It is a rare condition with a challenging differential diagnosis with obsessive-compulsive disorders, mental retardation and catatonia, and its existence as an independent syndrome is still debated by authors and not included by classification systems. Therefore, its treatment management is not well-defined and it still represents a clinical challenge for clinicians. Currently, the main proposal is a mix of antidepressant, antipsychotic, psychoeducation, psychotherapy and biological non-pharmacological interventions. Hereby, we describe a case of an 18-year-old male patient who presented debilitating slowness and severe impairment. Managing his treatment was particularly challenging for clinicians and was ultimately improved with escitalopram 30 mg/day combined with memantine 10 mg/day and amisulpride 400 mg/day. View Full-Text
Keywords: antidepressant; antipsychotic; case report; co-medication; differential diagnosis; obsessive-compulsive disorder; personalized treatment; psychopharmacology; tailoring; treatment antidepressant; antipsychotic; case report; co-medication; differential diagnosis; obsessive-compulsive disorder; personalized treatment; psychopharmacology; tailoring; treatment
MDPI and ACS Style

Reddy, B.; de Filippis, R.; Nocera, A.; Das, S. Primary Obsessive Slowness: A Complex Presentation and Treatment Difficulties. Future Pharmacol. 2022, 2, 153-159. https://doi.org/10.3390/futurepharmacol2020012

AMA Style

Reddy B, de Filippis R, Nocera A, Das S. Primary Obsessive Slowness: A Complex Presentation and Treatment Difficulties. Future Pharmacology. 2022; 2(2):153-159. https://doi.org/10.3390/futurepharmacol2020012

Chicago/Turabian Style

Reddy, Balaswamy, Renato de Filippis, Alessandra Nocera, and Soumitra Das. 2022. "Primary Obsessive Slowness: A Complex Presentation and Treatment Difficulties" Future Pharmacology 2, no. 2: 153-159. https://doi.org/10.3390/futurepharmacol2020012

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop